Both in our cohort and in the TCGA cohort, however, we found that the alteration of the cell cycle pathway or CDKN2A itself was a less important factor than TP53 missense mutation to promote poor tumor differentiation, as shown in Table 1, Additional file 4: Table S7_Multivariate Logistic Regression of Core Gene Pathway Alterations for Tumor Differentiation in KRASmut PDAC, and Additional file 4: Table S14_Core Gene Alterations and Association with Tumor Differentiation in KRASmut PDAC in the TCGA cohort. The gene discussed is TP53; the disease is neoplasm.